Menopause timing, hormone therapy, epigenetic aging, and breast cancer outcomes: a secondary analysis of the PLCO Cancer Screening Trial

medRxiv · 2026 · PMC13692351
OA: gold
📄 Open PDF
⚙ AI-generated summary by qwen3.7-flash, 2026-10-25 ⓘ

This secondary analysis of the PLCO Cancer Screening Trial examined associations between menopause timing, hormone therapy use, epigenetic aging, and breast cancer outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00